INNOVATE Corp Q1 Revenue Climbs 33% to $364.8M; EBITDA Soars 174%

VATEVATE

INNOVATE Corp reported Q1 revenue of $364.8 million, up 33% year-over-year, with adjusted EBITDA climbing 174% to $19.7 million and net loss per share narrowing 31.7% to $1.29. Infrastructure led growth with $357.9 million revenue (+35.1%) and $23.0 million EBITDA, while MediBeacon secured CE mark approval.

1. Consolidated First Quarter Results

INNOVATE Corp’s consolidated Q1 revenue rose 33.0% to $364.8 million from $274.2 million a year earlier. The company narrowed its net loss to $17.2 million, or $1.29 per share, and boosted adjusted EBITDA by 173.6% to $19.7 million.

2. Infrastructure Segment Performance

DBM Global generated $357.9 million in Q1 revenue, up 35.1% from $264.9 million, and contributed $9.3 million in net income. Adjusted EBITDA increased to $23.0 million, supported by strong backlog visibility of $1.8 billion and expanding AI infrastructure and advanced manufacturing projects.

3. Life Sciences Milestones

MediBeacon received CE mark approval for its Transdermal GFR Monitor and reusable sensor, paving the way for European commercialization and early U.S. clinical adoption. R2 Technologies posted $1.6 million in Q1 revenue, with demand of $2.2 million and a backlog of nearly 160 systems, led by a 58.6% increase in international sales.

4. Spectrum Broadcasting Challenges

Spectrum Broadcasting’s Q1 revenue fell to $5.3 million from $6.2 million, and net loss widened to $6.5 million. Adjusted EBITDA halved to $0.7 million due to advertising softness and network cancellations, though collaborative 5G broadcast trials offer potential H2 2026 funding opportunities.

Sources

F